evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,935 questions · 1,986 findings · 260 reviews · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 503 · 25.3%GRADE not reported 76 · 3.8%Very low 593 · 29.9%Low 509 · 25.6%Moderate 241 · 12.1%High 64 · 3.2%

Intervention not reported

Interferon beta‐1a (Avonex, Rebif) (Direct evidence; 3 RCTs; 1629 participants) · Patients with RRMS Interventions: alemtuzumab, azathriopine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…

The intervention probably leads to lower interferon beta‐1a (Avonex, Rebif) (Direct evidence; 3 RCTs; 1629… (moderate certainty).

1 finding from 1 review

Intervention not reported

Mitoxantrone (Direct evidence; 1 RCT; 51 participants) · Patients with RRMS Interventions: alemtuzumab, azathriopine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…

The intervention may leads to lower mitoxantrone (Direct evidence; 1 RCT; 51 participants) (low certainty).

1 finding from 1 review

Intervention not reported

Interferon beta‐1a (Avonex, Rebif) (Direct evidence; 2 RCTs; 1069 participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…

The intervention showed no clear difference in interferon beta‐1a (Avonex, Rebif) (Direct evidence; 2 RCTs; 1069… (low certainty).

1 finding from 1 review

Intervention not reported

Mitoxantrone (Direct evidence; 1 RCT; 51 participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…

It is very uncertain whether the intervention changes mitoxantrone (Direct evidence; 1 RCT; 51 participants) (very low certainty).

1 finding from 1 review

Intervention not reported

Ponesimod No direct evidence · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…

It is very uncertain whether the intervention changes ponesimod No direct evidence (very low certainty).

1 finding from 1 review

Intervention not reported

Ponesimod No direct evidence · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…

It is very uncertain whether the intervention changes ponesimod No direct evidence (very low certainty).

1 finding from 1 review

Intervention not reported

Interferon beta‐1a (Rebif, Avonex) (Direct evidence; 1 RCT; 897 participants) · Patients with RRMS Interventions: Alemtuzumab, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate, interferon…

It is very uncertain whether the intervention changes interferon beta‐1a (Rebif, Avonex) (Direct evidence; 1 RCT; 897… (very low certainty).

1 finding from 1 review

Intervention not reported

Mitoxantrone (Direct evidence; 1 RCT; 53 participants) · Patients with RRMS Interventions: Alemtuzumab, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate, interferon…

It is very uncertain whether the intervention changes mitoxantrone (Direct evidence; 1 RCT; 53 participants) (very low certainty).

1 finding from 1 review

Intervention not reported

Interferon beta‐1a (Avonex, Rebif) (Direct evidence; 1 RCT; 560 participants) · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins, interferon beta 1a ‐1b,…

The intervention may leads to lower interferon beta‐1a (Avonex, Rebif) (Direct evidence; 1 RCT; 560… (low certainty).

1 finding from 1 review

Intervention not reported

Ponesimod No direct evidence · Patients with RRMS Interventions: Alemtuzumab, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate, interferon…

It is very uncertain whether the intervention changes ponesimod No direct evidence (very low certainty).

1 finding from 1 review

Intervention not reported

Finding 20. There are some considerations for designing interventions that promote physical activity for bipolar disorder. These include sequencing multicomponent lifestyle changes, technology, incentives, and health promotion strategies that are ... · s where they do not wish or feel the need to participate in physical activity.
1 finding from 1 review

Thrombo‐aspiration alone vs stent‐retrieval thrombectomy alone

Functional independence · people with acute ischemic stroke

Thrombo‐aspiration alone showed no clear difference in functional independence at 3 months (mRS 0 to 2) (primary outcome) compared with stent‐retrieval thrombectomy alone (high certainty).

1 finding from 1 review

Thrombo‐aspiration alone vs stent‐retrieval thrombectomy alone

Successful reperfusion (mTICI 2b to 3) postprocedure · people with acute ischemic stroke

Thrombo‐aspiration alone showed no clear difference in successful reperfusion (mTICI 2b to 3) postprocedure compared with stent‐retrieval thrombectomy alone (high certainty).

1 finding from 1 review

Thrombo‐aspiration alone vs stent‐retrieval thrombectomy alone

All‐cause mortality within 3 months · people with acute ischemic stroke

Thrombo‐aspiration alone showed no clear difference in all‐cause mortality within 3 months compared with stent‐retrieval thrombectomy alone (high certainty).

1 finding from 1 review

Thrombo‐aspiration alone vs stent‐retrieval thrombectomy alone

Intracranial hemorrhage on imaging at 24 hours · people with acute ischemic stroke

Thrombo‐aspiration alone showed no clear difference in intracranial hemorrhage on imaging at 24 hours compared with stent‐retrieval thrombectomy alone (high certainty).

1 finding from 1 review